Dupixent & Cutaneous T-Cell Lymphoma Lawsuit – Free Case Review
If you used Dupixent (dupilumab) and were diagnosed with cutaneous T-cell lymphoma (CTCL) or another T-cell lymphoma, you may qualify for a free case review. Lawsuits allege the manufacturer failed to adequately warn of lymphoma risk. Confidential, no obligation.
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
You may qualify if:
- You used Dupixent (dupilumab) for eczema, asthma, or another approved condition
- You were later diagnosed with cutaneous T-cell lymphoma (CTCL) or another T-cell lymphoma
- Your diagnosis occurred during or after Dupixent use
- Statutes of limitations vary by state—contact us soon
You can submit even if you don't have records yet.
Dupixent & CTCL Lawsuit News & Updates HubWho May Qualify
You may be eligible for a free case review if you used Dupixent and were later diagnosed with cutaneous T-cell lymphoma (CTCL) or another T-cell lymphoma. The following factors may indicate eligibility:
- Used Dupixent for eczema (atopic dermatitis), asthma, chronic rhinosinusitis, or another approved use
- Diagnosed with CTCL (e.g., mycosis fungoides, Sézary syndrome) or another T-cell lymphoma
- Diagnosis occurred during or after Dupixent use
If you believe you may qualify, we encourage you to submit your information for a free case review. Our review process helps determine if you may be connected with an independent law firm for evaluation of a potential claim.
What is Dupixent?
Dupixent (dupilumab) is a biologic medication approved by the FDA to treat moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and other conditions. It works by blocking certain proteins involved in inflammation.
Lawsuits allege that Dupixent may be associated with an increased risk of cutaneous T-cell lymphoma (CTCL) in some patients and that the manufacturer did not adequately warn about this risk. If you used Dupixent and were diagnosed with CTCL, a free case review can help you understand your options.
Dupixent and Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma that primarily affects the skin. Mycosis fungoides and Sézary syndrome are common forms. Plaintiffs in Dupixent litigation allege that the drug may increase the risk of CTCL or worsen or unmask pre-existing CTCL, and that the manufacturer failed to warn patients and doctors.
If you used Dupixent and were diagnosed with CTCL or another T-cell lymphoma, you may have legal options. A free case review can help determine whether your situation may qualify for evaluation by an independent law firm.
Dupixent & CTCL Litigation Updates
Dupixent litigation is in early stages. Lawsuits allege that the manufacturer did not adequately warn about the risk of cutaneous T-cell lymphoma (CTCL) and other T-cell lymphomas. No federal multidistrict litigation (MDL) has been established yet. For the latest developments, see our Dupixent & CTCL Lawsuit News & Updates hub.
Current Status
- Litigation is developing; individual cases may be filed in state or federal court
- No MDL consolidation yet; check our news hub for updates
- Statutes of limitations vary by state—contact us for a free case review
For the latest Dupixent lawsuit news and legal developments, see our dedicated Dupixent & CTCL Lawsuit News & Updates hub.
Evidence and Allegations
Plaintiffs in Dupixent litigation allege that the drug may be associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturer knew or should have known of this risk but failed to adequately warn patients and healthcare providers. Scientific and regulatory developments in this area are evolving.
If you used Dupixent and were diagnosed with CTCL, a free case review can help you understand whether you may have a claim and be connected with an independent law firm for evaluation.
Dupixent & CTCL Legal Resources
Stay informed with our Dupixent lawsuit news hub for legal case updates and litigation developments.
Latest Dupixent lawsuit news and legal developments. Updated regularly.
Legal disclaimer
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
Start Your Free Dupixent & CTCL Case Review
Time limits may apply. Contact us today for a free, confidential case review to see if you may qualify and be connected with a law firm handling Dupixent and cutaneous T-cell lymphoma claims.